Is Jaguar Health, Inc. overvalued or undervalued?

As of 9 August 2017, Jaguar Health, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently overvalued given its financial metrics, including a Price to Book Value of 1.20, an EV to Sales ratio of 3.18, and a staggering ROE of -742.25%. These figures indicate significant financial distress and a lack of profitability, which is further underscored by its loss-making status reflected in the P/E ratio being not applicable.
In comparison to its peers, Jaguar Health, Inc. shows a less favorable position; for instance, SeqLL, Inc. has an EV to EBITDA of -8.8835, while Agile Therapeutics, Inc. has an EV to EBITDA of -0.5982, both indicating more manageable valuations within the same risky category. The company's recent stock performance has been notably poor, with a year-to-date return of -89.31%, contrasting sharply with the S&P 500's modest gain of 2.44% in the same period, reinforcing the notion that Jaguar Health, Inc. is overvalued in its current state.